Assembly Biosciences, Inc. (ASMB): Price and Financial Metrics
GET POWR RATINGS... FREE!
ASMB Stock Price Chart Interactive Chart >
ASMB Price/Volume Stats
| Current price | $1.04 | 52-week high | $2.42 |
| Prev. close | $1.07 | 52-week low | $0.82 |
| Day low | $1.01 | Volume | 111,100 |
| Day high | $1.06 | Avg. volume | 258,198 |
| 50-day MA | $1.45 | Dividend yield | N/A |
| 200-day MA | $1.67 | Market Cap | 54.02M |
Assembly Biosciences, Inc. (ASMB) Company Bio
Assembly Biosciences develops oral therapies for intractable infectious diseases in the United States. The company focuses on the hepatitis B virus and C. difficile-associated infections. The company was founded in 2005 and is based in New York, New York.
Latest ASMB News From Around the Web
Below are the latest news stories about ASSEMBLY BIOSCIENCES INC that investors may wish to consider to help them evaluate ASMB as an investment opportunity.
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-e |
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection ProgramsAssembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). For the Phase 1b trial of 3733, the dose selected for the first cohort was 50 mg. A dose of 100 mg has been selected for the third cohort, for which dosing is ongoing, with initial data anticipated in Q1 of 2023. Related: Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection. In the 50 m |
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNAInitial ABI-4334 Phase 1a single-dose 30 mg cohort demonstrated pharmacokinetic profile supportive of once-daily oral dosing and provides early indication that ABI-4334's very high potency seen preclinically can be accessed clinicallyNo serious adverse events or significa |
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334 (4334). 4334 is an investigat |
Analysts Offer Insights on Healthcare Companies: Emergent Biosolutions (EBS), Inovio Pharmaceuticals (INO) and Assembly Biosciences (ASMB)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Emergent Biosolutions (EBS – Research Report), Inovio Pharmaceuticals (INO – Research Report) and Assembly Biosciences (ASMB – Research Report). Emergent Biosolutions (EBS) Chardan Capital analyst Keay Nakae reiterated a Buy rating on Emergent Biosolutions today and set a price target of $55.00. The company's shares closed last Tuesday at $19.73, close to its 52-week low of $18.00. According to TipRanks. |
ASMB Price Returns
| 1-mo | -22.96% |
| 3-mo | N/A |
| 6-mo | -37.35% |
| 1-year | -52.51% |
| 3-year | -93.09% |
| 5-year | -98.10% |
| YTD | -20.00% |
| 2022 | -44.21% |
| 2021 | -61.49% |
| 2020 | -70.43% |
| 2019 | -9.55% |
| 2018 | -50.01% |
Continue Researching ASMB
Want to see what other sources are saying about Assembly Biosciences Inc's financials and stock price? Try the links below:Assembly Biosciences Inc (ASMB) Stock Price | Nasdaq
Assembly Biosciences Inc (ASMB) Stock Quote, History and News - Yahoo Finance
Assembly Biosciences Inc (ASMB) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...